With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Sedana Medical AB (publ) has received market approval for Sedaconda[®] (isoflurane) for inhaled seda…
Sedana Medical AB (publ) plans to present its fourth quarter and Year-End Report for 2022 in an audi…
Sedana Medical AB (publ) (the "Company" or "Sedana Medical") announced on 19 January 2023 that Nasda…